Dinaciclib is a potent kinase inhibitor that targets cyclin-dependent kinases, including CDK1, CDK2, CDK5, and CDK9, and is currently studied in clinical trials for conditions such as relapsed or refractory… Read more
Dinaciclib is a potent kinase inhibitor that targets cyclin-dependent kinases, including CDK1, CDK2, CDK5, and CDK9, and is currently studied in clinical trials for conditions such as relapsed or refractory multiple myeloma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and various solid tumors. This category provides essential materials for pharmaceutical research, including the Dinaciclib active pharmaceutical ingredient, its related impurities, and stable isotope-labelled compounds. Laboratories utilize these high-quality reference standards for comprehensive impurity profiling, method development, and rigorous quality control protocols during drug manufacturing. The inclusion of stable isotope-labelled analogs, such as Dinaciclib-13C3, facilitates accurate quantitative analysis and internal standardization in complex matrices, ensuring the reliability of data throughout the drug development lifecycle. By supplying these critical analytical tools, this collection supports the precise characterization of the parent compound and its potential degradation products or metabolic byproducts.